TY - JOUR
T1 - The first BILGENSA Research Network workshop in Zambia
T2 - identifying research priorities, challenges and needs in genital bilharzia in Southern Africa
AU - Ndubani, Rhoda
AU - Lamberti, Olimpia
AU - Kildemoes, Anna
AU - Hoekstra, Pytsje
AU - Fitzpatrick, Jennifer
AU - Kelly, Helen
AU - Vwalika, Bellington
AU - Randrianasolo, Bodo
AU - Sturt, Amy
AU - Kayuni, Seke
AU - Choko, Augustine
AU - Kasese, Nkatya
AU - Kjetland, Eyrun
AU - Nemungadi, Takalani
AU - Mocumbi, Sibone
AU - Samson, Anna
AU - Ntapara, Elizabeth
AU - Thomson, Anifrid
AU - Danstan, Elizabeth
AU - Chikwari, Chido Dziya
AU - Martin, Kevin
AU - Rabiu, Ibrahim
AU - Terkie, Gifty
AU - Chaima, David
AU - Kasoka, Manuel
AU - Joeker, Karoline
AU - Arenholt, Louise Thomsen Schmidt
AU - Leutscher, Peter
AU - Stothard, Russel
AU - Rabozakandria, Oliva
AU - Gouvras, Anouk
AU - Munthali, Tendai
AU - Hameja, Grace
AU - Kanfwa, Paul
AU - Hikabasa, Halwindi
AU - Ayles, Helen
AU - Shanaube, Kwame
AU - Bustinduy, Amaya L.
N1 - Copyright: © 2024 Ndubani R et al.
[version 1; peer review: 1 approved, 3 approved with reservations]
PY - 2024/7/10
Y1 - 2024/7/10
N2 - Female genital schistosomiasis (FGS) and male genital schistosomiasis (MGS) are gender-specific manifestations of urogenital schistosomiasis. Morbidity is a consequence of prolonged inflammation in the human genital tract caused by the entrapped eggs of the waterborne parasite, Schistosoma (S.) haematobium. Both diseases affect the sexual and reproductive health (SRH) of millions of people globally, especially in sub-Sahara Africa (SSA). Awareness and knowledge of these diseases is largely absent among affected communities and healthcare workers in endemic countries. Accurate burden of FGS and MGS disease estimates, single and combined, are absent, mostly due to the absence of standardized methods for individual or population-based screening and diagnosis. In addition, there are disparities in country-specific FGS and MGS knowledge, research and implementation approaches, and diagnosis and treatment. There are currently no WHO guidelines to inform practice. The BILGENSA (Genital Bilharzia in Southern Africa) Research Network aimed to create a collaborative multidisciplinary network to advance clinical research of FGS and MGS across Southern African endemic countries. The workshop was held in Lusaka, Zambia over two days in November 2022. Over 150 researchers and stakeholders from different schistosomiasis endemic settings attended. Attendees identified challenges and research priorities around FGS and MGS from their respective countries. Key research themes identified across settings included: 1) To increase the knowledge about the local burden of FGS and MGS; 2) To raise awareness among local communities and healthcare workers; 3) To develop effective and scalable guidelines for disease diagnosis and management; 4) To understand the effect of treatment interventions on disease progression, and 5) To integrate FGS and MGS within other existing sexual and reproductive health (SRH) services. In its first meeting, the BILGENSA Network set forth a common research agenda across S. haematobium endemic countries for the control of FGS and MGS.
AB - Female genital schistosomiasis (FGS) and male genital schistosomiasis (MGS) are gender-specific manifestations of urogenital schistosomiasis. Morbidity is a consequence of prolonged inflammation in the human genital tract caused by the entrapped eggs of the waterborne parasite, Schistosoma (S.) haematobium. Both diseases affect the sexual and reproductive health (SRH) of millions of people globally, especially in sub-Sahara Africa (SSA). Awareness and knowledge of these diseases is largely absent among affected communities and healthcare workers in endemic countries. Accurate burden of FGS and MGS disease estimates, single and combined, are absent, mostly due to the absence of standardized methods for individual or population-based screening and diagnosis. In addition, there are disparities in country-specific FGS and MGS knowledge, research and implementation approaches, and diagnosis and treatment. There are currently no WHO guidelines to inform practice. The BILGENSA (Genital Bilharzia in Southern Africa) Research Network aimed to create a collaborative multidisciplinary network to advance clinical research of FGS and MGS across Southern African endemic countries. The workshop was held in Lusaka, Zambia over two days in November 2022. Over 150 researchers and stakeholders from different schistosomiasis endemic settings attended. Attendees identified challenges and research priorities around FGS and MGS from their respective countries. Key research themes identified across settings included: 1) To increase the knowledge about the local burden of FGS and MGS; 2) To raise awareness among local communities and healthcare workers; 3) To develop effective and scalable guidelines for disease diagnosis and management; 4) To understand the effect of treatment interventions on disease progression, and 5) To integrate FGS and MGS within other existing sexual and reproductive health (SRH) services. In its first meeting, the BILGENSA Network set forth a common research agenda across S. haematobium endemic countries for the control of FGS and MGS.
KW - FGS
KW - Female genital schistosomiasis
KW - MGS
KW - Schistosoma haematobium
KW - Southern Africa
KW - male genital schistosomiasis
KW - needs
KW - priorities
KW - research
UR - http://www.scopus.com/inward/record.url?scp=85201897971&partnerID=8YFLogxK
U2 - 10.12688/wellcomeopenres.22429.1
DO - 10.12688/wellcomeopenres.22429.1
M3 - Journal article
C2 - 39170763
SN - 2398-502X
VL - 9
JO - Wellcome Open Research
JF - Wellcome Open Research
M1 - 360
ER -